Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Perspective Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Proposed Public Offering
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Divests Brachytherapy Business
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Changes to the Board of Directors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer
From Perspective Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.